💫 Phaim is all about people and purpose. 🏆 The purpose: transformational novel therapies for people with autoimmune disease. 💪 The people: those that consistently make a difference. With that: ⭐ Today, we are beyond excited to welcome Parker Moss, one of the shining stars in the UK biotech ecosystem. ⭐ Parker Moss is a healthcare & life sciences leader and investor, with a focus on cancer and rare disease. He has been a member of the executive teams at: Exscientia (now Recursion), a NASDAQ listed small molecule Generative AI drug discovery company; Genomics England, which delivered the 100,000 Genomes Project and provides whole genome sequencing in the NHS for cancer and rare disease; Fidelity’s F-Prime at Eight Roads VC funds where he was a venture partner and led the investment before joining Owkin, a Federated AI cancer focussed biotech; Great Ormond Street Children’s Hospital and Virgin Care where he led technology. Parker also holds several non-executive roles, including: a NED of Cancer Research UK’s Horizon board; SAB member of LifeArc's £100M paediatric cancer programme; and a director of the UK’s Rare Therapies Launch Pad. He was previously a member of the UK Secretary of State for Health’s technology advisory board. Parker holds a Natural Sciences degree in Physics and Philosophy from Durham University. Parker's interest in immune escape and immune regulation has drawn him to the elegant platform technology of Phaim and it's novel approach to T-Reg immune modulation.
Phaim Pharma Ltd’s Post
More Relevant Posts
-
There is no more noble mission for me than trying to tackle unmet need for patients with Owkin defining a new category of company, an end to end data driven biotech powered by the most powerful data platform and ai engines. This Is taking 120% of my time, my passion. I dream of OWKIN, I eat OWKIN, and there is no other mission I want to achieve. No other social role i wanna play. To power the company, we are partnering with amazing pharma such as Sanofi, Bristol Myers Squibb, MSD, Servier...learning and building together, from the best academic hospitals such as Gustave Roussy, CHUV / Centre hospitalier universitaire vaudois, Memorial Sloan Kettering Cancer Center among so many more (54 of the top academic centers in the world), Amazon Web Services (AWS) as a great cloud provider,Hugging Face to build models and vecause they just rock, 10x Genomics to create MOSAIC - the largest spatial T database in the world, Tribun Health, AI-powered Pathology for our diagnostics tools and to validate complex biology breakthrough, SUN bioscience for complex models patients derived. And so many many more... But this ecosystem has to be completed, and I have been proud to help cofound at inception Bioptimus to create the first multiscale foundation in biology that will improve performance, robustness and explainability of all of our al tasks and of so many other great companies, and is proud too to have helped cofound Cure51 announced today, that will drive amzing discoveries in outlier cancer biology. Proud of Simon Istolainen and Nicolas Wolikow for all the work done so far and the amazing ambition, to Alexandre SYROTA impact and of course to Fabulous Fab fabrice andre. I don’t play any operational or board role in either of those companies at all, and am more focused than ever on OWKIN. 🎧 I also want to thank the amazing Sofinnova Partners team, mega brilliant Edward Kliphuis and Simon Turner - both bringing something rare in vc: fun. Big up to Joanna Soroka, PhD for joining the board and Amol Sarva that share coolness and grey salt and pepper beard with me. I am very modest. A special thanks finally to Antoine Papiernik - who validates investment in both of those companies, with the vision of innovation, challenge, and moonshot. Go Owkin galaxy and friends. Let's create medical moments together, at scale. Because patients cannot wait.
-
Founder Of Manentia AI | Health Tech industry | AI & ML Innovation in Medical Imaging Diagnosis system
🌟 Exciting news in the healthcare startup world! Cure51 raises €15M in seed funding to revolutionize cancer survival rates. Their innovative approach aligns perfectly with our mission at Manentia AI to enhance early disease detection, particularly in conditions like lung cancer. Together, we're driving advancements in medical technology to improve patient outcomes and save lives. Thomas Clozel Cure51 #HealthTech #CancerResearch #StartupFunding 🚀
There is no more noble mission for me than trying to tackle unmet need for patients with Owkin defining a new category of company, an end to end data driven biotech powered by the most powerful data platform and ai engines. This Is taking 120% of my time, my passion. I dream of OWKIN, I eat OWKIN, and there is no other mission I want to achieve. No other social role i wanna play. To power the company, we are partnering with amazing pharma such as Sanofi, Bristol Myers Squibb, MSD, Servier...learning and building together, from the best academic hospitals such as Gustave Roussy, CHUV / Centre hospitalier universitaire vaudois, Memorial Sloan Kettering Cancer Center among so many more (54 of the top academic centers in the world), Amazon Web Services (AWS) as a great cloud provider,Hugging Face to build models and vecause they just rock, 10x Genomics to create MOSAIC - the largest spatial T database in the world, Tribun Health, AI-powered Pathology for our diagnostics tools and to validate complex biology breakthrough, SUN bioscience for complex models patients derived. And so many many more... But this ecosystem has to be completed, and I have been proud to help cofound at inception Bioptimus to create the first multiscale foundation in biology that will improve performance, robustness and explainability of all of our al tasks and of so many other great companies, and is proud too to have helped cofound Cure51 announced today, that will drive amzing discoveries in outlier cancer biology. Proud of Simon Istolainen and Nicolas Wolikow for all the work done so far and the amazing ambition, to Alexandre SYROTA impact and of course to Fabulous Fab fabrice andre. I don’t play any operational or board role in either of those companies at all, and am more focused than ever on OWKIN. 🎧 I also want to thank the amazing Sofinnova Partners team, mega brilliant Edward Kliphuis and Simon Turner - both bringing something rare in vc: fun. Big up to Joanna Soroka, PhD for joining the board and Amol Sarva that share coolness and grey salt and pepper beard with me. I am very modest. A special thanks finally to Antoine Papiernik - who validates investment in both of those companies, with the vision of innovation, challenge, and moonshot. Go Owkin galaxy and friends. Let's create medical moments together, at scale. Because patients cannot wait.
Cure51 raises a €15M Seed round aiming to crack the code on cancer survival | TechCrunch
https://techcrunch.com
-
The University of Toronto's Temerty Centre for Artificial Intelligence Research and Education in Medicine (T-CAIREM) and FACIT, a commercialization venture firm, have joined forces to revolutionize cancer research through the power of AI. Can you imagine the possibilities when cutting-edge technology meets the fight against cancer? Their collaborative efforts not only aim to accelerate advancements in AI-powered cancer research but also drive economic development in Ontario. Together, they are on a mission to benefit cancer patients and make a lasting impact in the field. What are your thoughts on this groundbreaking partnership? How do you think AI can transform the future of cancer research? Share your thoughts below! 👇 https://lnkd.in/gJDRjW-S #CancerResearch #ArtificialIntelligence #AI
Collaboration aims to boost cancer research and develop innovation economy in Ontario | IT World Canada News
https://www.itworldcanada.com
-
The University of Toronto's Temerty Centre for Artificial Intelligence Research and Education in Medicine (T-CAIREM) and FACIT, a commercialization venture firm, have joined forces to revolutionize cancer research through the power of AI. Can you imagine the possibilities when cutting-edge technology meets the fight against cancer? Their collaborative efforts not only aim to accelerate advancements in AI-powered cancer research but also drive economic development in Ontario. Together, they are on a mission to benefit cancer patients and make a lasting impact in the field. What are your thoughts on this groundbreaking partnership? How do you think AI can transform the future of cancer research? Share your thoughts below! 👇 https://lnkd.in/gHHg8Kyp #CancerResearch #ArtificialIntelligence #AI
Collaboration aims to boost cancer research and develop innovation economy in Ontario | IT World Canada News
https://www.itworldcanada.com
-
🔬 Enara Bio Raises $32.5M to Advance Cancer Immunotherapy! 💪 Oxford-based Enara Bio just secured $32.5M in Series B funding to accelerate its mission of developing TCR-based immunotherapies against unique cancer targets. 🌍 Key Highlights: • Funding Led by Pfizer Ventures and M Ventures 🎉 with support from RA Capital, Samsara BioCapital, SV Health Investors, and new investor The Francis Crick Institute. • Board Strengthened with the addition of Rana Al-Hallaq from Pfizer Ventures and Bauke Anninga from M Ventures. What Sets Enara Bio Apart: 🔹 EDAPT Platform – a groundbreaking technology for discovering "Dark Antigens" unique to tumor cells. 🔹 Combines bioinformatics, immunopeptidomics, and RNA in situ hybridization for precise targeting. 🔹 Focuses on solid tumors, ensuring cancer-specificity and consistent intratumoral expression. “This funding propels us forward to bring novel immunotherapies to cancer patients in need.” – Kevin Pojasek, CEO Enara Bio is pushing the boundaries of cancer treatment with cutting-edge science! 🧬 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing! #CancerResearch #Immunotherapy #Biotech #EnaraBio #SeriesBFunding #Innovation #HealthTech #FutureTechly
-
-
Founder and investor, LifeX Ventures, Aikito, CornerUp, Knotel, Peek, Virgin Mobile, McKinsey, Stanford and Columbia
Shouldn't we study people who live the longest? The folks who beat the toughest cancers? The supersurvivors? It's obvious we should - we should put 1000% into finding and analyzing everything we possibly can about those 1000-to-1 odds survivors. Yet we don't... Actually, now we do. Cure51 announced this week to the world about their new financing. LifeX Ventures is excited to be part of it -- not only because it's completely obvious that *someone* should study these cases, but because: - the time is now, with new tools for capturing -omics from patients and tumor samples that were impossible before - and new tools for analyzing this huge variety of data, at a moment that AI tools are accelerating amazingly, - but importantly, the *data* is not accelerating. There are just a few thousand cases out there of these impossible supersurvivors. The AI models aren't useful without the data. Cure51 is going to go get it It's a thrill to watch the progress Nicolas Wolikow, Simon Istolainen, Alexandre SYROTA, and Thomas Clozel have already made, and doing it from *Paris* (watch out Cleveland and Palo Alto...) See below about the 15mm Euro financing where LifeX Ventures joined with Sofinnova Investments , Hitachi Ventures , Olivier Pomel and other stars. A fine piece by Mike Butcher ✍️ https://lnkd.in/eTfvNf3D
Cure51 raises a €15M seed round aiming to crack the code on cancer survival | TechCrunch
https://techcrunch.com
-
🧱 Builders: Kevin Parker - President & CEO, Founder @ Cartography Biosciences Join us for an exclusive conversation with Kevin Parker, CEO and co-founder of Cartography Biosciences, on our latest podcast episode of BIOS Builders. Kevin delves into his transition from a Ph.D. at Stanford focusing on basic biology to launching a startup aimed at transforming cancer therapy with targeted immunotherapies and an innovative antigen atlas. This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Learn about the inception of Cartography Biosciences, the development of their transformative technology, and the challenges of navigating the biotech startup landscape amidst a global pandemic. Kevin's insights into the future of precision medicine, the importance of interdisciplinary teams, and the journey towards their first clinical programs offer invaluable lessons for anyone interested in the cutting edge of cancer research and the entrepreneurial journey in life sciences. Don't miss this deep dive into the mission, science, and strategy behind Cartography Biosciences' quest to expand the horizons of cancer treatment. Tune in: https://buff.ly/4f2OnmH This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Read more about the exciting partnership here: https://buff.ly/4cC0sxo #BiotechInnovation #PrecisionMedicine #CancerTherapy #StartupJourney #TargetedImmunotherapy #LifeSciences #Entrepreneurship #ClinicalResearch #FutureOfHealthcare #TechBio #BiotechStartup #CancerResearch #InterdisciplinaryTeams #PhDLife #InnovativeTechnology
-
-
🧱 Builders: Kevin Parker - President & CEO, Founder @ Cartography Biosciences Join us for an exclusive conversation with Kevin Parker, CEO and co-founder of Cartography Biosciences, on our latest podcast episode of BIOS Builders. Kevin delves into his transition from a Ph.D. at Stanford focusing on basic biology to launching a startup aimed at transforming cancer therapy with targeted immunotherapies and an innovative antigen atlas. This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Learn about the inception of Cartography Biosciences, the development of their transformative technology, and the challenges of navigating the biotech startup landscape amidst a global pandemic. Kevin's insights into the future of precision medicine, the importance of interdisciplinary teams, and the journey towards their first clinical programs offer invaluable lessons for anyone interested in the cutting edge of cancer research and the entrepreneurial journey in life sciences. Don't miss this deep dive into the mission, science, and strategy behind Cartography Biosciences' quest to expand the horizons of cancer treatment. Tune in: https://buff.ly/4f2OnmH This episode also explores Cartography Biosciences' recent collaboration with Gilead, highlighting the groundbreaking potential of their partnership in revolutionizing cancer treatment. Read more about the exciting partnership here: https://buff.ly/4cC0sxo #BiotechInnovation #PrecisionMedicine #CancerTherapy #StartupJourney #TargetedImmunotherapy #LifeSciences #Entrepreneurship #ClinicalResearch #FutureOfHealthcare #TechBio #BiotechStartup #CancerResearch #InterdisciplinaryTeams #PhDLife #InnovativeTechnology
-
-
Paris, 14 June 2024 BREAKING NEWS! We are pleased to announce that Rosetta Omics has received the Bpifrance grant : BFT emergence to finance its deeptech program: two POCs studies in two solid tumors. BFT Emergence is a non-dilutive grant directed for deeptech startups to allow for the maximum financing of its R&D programs to reach the market. It is granted after a rigorous due diligence process of many months. The grant is part of the Deeptech plan financed by the France 2030 Program launched by the French State. Rosetta is a deeptech startup leading the way to precision medicine in oncology. We use spatial, multiomics (proteomics, metabolomics and lipidomics) and AI to predict the response to treatments in cancer patients and aid biopharma companies with patient stratification and biomarker discovery, and target validation. Many more great news in the pipeline, so stay tuned! #Bpifrance #fundraising #grants #oncology #cancer #multiomics #AI #ML #nondilutive #deeptech #proteomics #France2030 Agoranov Medicen Paris Region Paris Saclay Cancer Cluster (PSCC) France Biotech HealthTech For Care Choose Paris Region Région Ile de France La French Tech Les Deeptech 🚀 Agence de l'innovation en santé European Innovation Council and SMEs Executive Agency (EISMEA) EIT Health Hello Tomorrow Blue Factory ESCP BioLabs
-
-
CEO, Cancer Center Informatics Society: Driving Precision Oncology & Applied Data Science, Innovating Digital Strategies, Transforming Clinical and Translational Research, Advancing AI Across Health Systems.
Breakthroughs in cancer research and clinical care are the result of collaborative efforts. The Cancer Center Informatics Society 's "Ci4CC" Initiatives Program is at the forefront of this mission, uniting Medical Oncology, Cancer Research, Translational Informatics, and Data Science to expand partnerships between NCI Designated & Community Cancer Centers with Biotech and Pharma. Our focus on key areas like Precision Oncology, Artificial Intelligence, and Genomics drives innovation in Cancer Center digital infrastructure. In 2024, we launched "Autonomous AI Research Agents" in partnership with Medeloop, an AI startup from Silicon Valley. This initiative leverages an innovative AI platform to transform complex cancer datasets into intuitive knowledge graphs, then giving users access to an autonomous AI research agent accelerating discoveries of novel cancer biomarkers. Join us at the Fall Symposium in Charleston, SC, this October [https://lnkd.in/gtFitkSW] to learn more about this exciting initiative. Looking forward to seeing you there! #CancerResearch #AI #PrecisionOncology #CancerCare #Innovation #Collaboration #ci4cc24
Autonomous AI Research Agents
ci4cc.org
